How Long Will I Have to Stay on Humira (Adalimumab) for Uveitis?
Uveitis Warning Signs That Need Care Right Away
Adalimumab keeps uveitis quiet. But a flare can still happen. Untreated eye inflammation can harm your sight. Call your eye doctor right away, or seek same-day care, if you notice any of these signs:
- New or worse eye pain
- New light sensitivity
- Sudden decreased vision, or any change in your vision
- A newly red and painful eye
- New floaters or flashing lights
Most flares calm down fast when treated early. Getting seen quickly protects your sight. This does not mean the medicine has failed.
Most days on adalimumab you will have no urgent symptoms, and that is the goal. Mild redness at the injection site, an occasional headache, or a little tiredness are common and can wait for a routine visit. The signs above are the ones that should not wait. When you are unsure, it is always fine to call your eye team and ask.
Humira (Adalimumab) for Uveitis at a Glance
There is no fixed number of weeks or months. Adalimumab is a maintenance medicine for uveitis, not a short course, and many people stay on it for a long time to keep the inflammation quiet. In a real-world study, people had been taking adalimumab for non-infectious uveitis for a median of more than three and a half years1. That length can feel daunting, but it reflects the medicine doing its job: holding down inflammation that would otherwise threaten your sight.
Adalimumab may control your uveitis but will not cure it, so doctors usually ask you to keep taking it even when your eye feels well2. The reason is concrete: in a clinical trial, most people whose eye inflammation was well controlled had it return after stopping adalimumab3. The encouraging news, covered below, is that restarting the medicine brought the inflammation back under control for those people.
How long you stay on adalimumab is a decision you make with the specialist who manages your uveitis, not a number you can read off a label. This page explains what the medicine is, how it is taken, its main risks, and what the research shows about staying on it, stopping, and starting again, so you can have a better-informed conversation at your next visit. It does not diagnose your eye or set your dose.
What Adalimumab Is and Why It Treats Uveitis
Uveitis is inflammation inside the eye, and it can affect the middle of the eye (intermediate), the back of the eye (posterior), or all parts at once (panuveitis)4. Uveitis can cause vision loss if it is not treated, and it can be chronic or come back4. That recurring nature is exactly why treatment is often measured in years, not weeks.
Adalimumab, sold under the brand name Humira, is a biologic medicine given by injection under the skin that is used to treat uveitis in adults and children2. It belongs to a group of medicines that help control an overactive immune response so that inflammation inside the eye settles down4. It is a prescription treatment, so a specialist chooses it and supervises it.
Steroids calm uveitis quickly, but taking them for months or years carries its own risks. Adalimumab is frequently chosen so you can lower or come off long-term steroids. In a real-world study, starting adalimumab was linked with a drop in oral steroid use, from about 87 of every 100 patients to about 25 of every 1001. Trading a daily steroid for a maintenance biologic is a big reason people find themselves on adalimumab for the long haul.
How You Take Adalimumab
Adalimumab comes as a liquid in prefilled syringes, dosing pens, or injection devices that you or a caregiver inject under the skin2. Your doctor decides how often you inject it based on your condition and age, and in a real-world study most people used the standard schedule of one injection every other week1. Your specialist sets your exact dose and timing, so follow their instructions rather than any general schedule you read online.
The strongest temptation on a long-term medicine is to skip doses once your eye feels normal. Resist it. Because adalimumab controls uveitis but does not cure it, keep using it even if you feel well, unless your doctor tells you to stop2. If cost, injection worries, or side effects make you want to stop, tell your doctor so you can solve the problem together rather than pausing on your own.
Before you start, your doctor will give you a skin test for tuberculosis and may order a blood test for hepatitis B, because adalimumab can reactivate a hidden infection2. This screening is a safety step, not a delay tactic. It is far easier to find and treat a hidden infection before you start than to manage one that flares up once your immune defenses are lowered.
Side Effects: What Is Common and What Means Call Your Doctor
The most common reactions to adalimumab are at the injection site, such as redness, and headaches can also occur2. These are usually mild and often ease over time. Rotating where you inject and letting the medicine reach room temperature before injecting can make the shots more comfortable; your nurse or pharmacist can show you how.
Adalimumab can lower your ability to fight infection and increase the chance of a serious infection, including tuberculosis2. This is the risk your care team watches most closely. It does not mean you will get a serious infection, but it does mean you should tell every clinician you see that you take adalimumab, stay up to date on recommended vaccines your doctor approves, and report signs of infection early rather than waiting them out.
Call your doctor right away if you develop symptoms such as shortness of breath, swelling of your feet, ankles, or lower legs, or chest pain2. Most people never see these, but knowing which symptoms cross from bothersome into report-it-now territory means you act quickly if they ever appear.
Who Should Wait or Avoid Adalimumab
An active infection, including untreated tuberculosis, needs to be treated before you can safely start adalimumab2. This is why the pre-treatment TB test matters so much. Waiting to clear an infection first is not the medicine being withheld from you; it is the step that lets you take it safely.
Tell your doctor if you have or have had hepatitis B, heart problems, or frequent or long-lasting infections, because these affect whether adalimumab is right for you2. Share your full medical history and every medicine you take, including over-the-counter products. Some combinations change the plan, and your doctor can only weigh that if they have the full picture.
Non-infectious uveitis of the middle and back of the eye is managed by an eye specialist, often a uveitis or retina specialist, sometimes together with a rheumatologist when a body-wide autoimmune condition is also involved. Starting, continuing, or stopping adalimumab sits with that team because they can weigh your eye, your overall health, and your other medicines at the same time.
How Long You Stay on It, Stopping, and the Long-Term Outlook
The honest answer to the title question is that adalimumab is usually a long-term treatment aimed at keeping your uveitis quiet, not a course with a set end date. In a real-world study, people with non-infectious uveitis had been on adalimumab for a median of more than three and a half years, and the medicine showed sustained effectiveness over that time1. For many people, staying on it is what keeps the eye calm.
In a clinical trial of people whose eye inflammation was well controlled, about 68 of every 100 who stopped adalimumab had their inflammation return, most within six months, compared with about 14 of every 100 who kept taking it3. Being in remission for a long time did not remove that risk: about 70 of every 100 people in the study had kept their uveitis controlled for more than two years on adalimumab, yet they still had a high risk of recurrence, even while also taking another medicine such as methotrexate3. In plain terms, feeling fine for a long stretch is not a reliable sign that you can safely come off.
Stopping is not a one-way door. Among the people whose inflammation returned after stopping, restarting adalimumab brought it back under control3. If you and your specialist do decide to try coming off, it is done as a planned step with close eye monitoring, weighing your relapse history and how much vision is at stake, not as an abrupt stop. The realistic outlook for most people is a long, stable stretch on the medicine with the option to restart if a flare occurs.
When to Call Your Doctor or Get Care the Same Day
Because adalimumab lowers your infection defenses, do not sit on symptoms that could signal infection. Contact your doctor promptly if you develop a fever, chills, a cough that will not go away, or other signs of an infection while taking adalimumab2. Catching an infection early is exactly why your team wants to hear from you sooner rather than later.
Because untreated eye inflammation can cause vision loss, see your eye doctor right away if you have new eye pain, redness, light sensitivity, or a change in your vision4. These can be signs your uveitis is flaring. Getting seen quickly gives your specialist the best chance to calm the flare before it affects your sight.
Between any urgent problems, expect regular follow-up visits while you are on adalimumab so your specialist can check that your eye stays quiet and that the medicine is being tolerated. Keep these appointments even when your eye feels perfect, because quiet uveitis and returning uveitis can look the same to you at home but different in an exam.
Common Questions About Adalimumab for Uveitis
Not necessarily, but plan for the long term rather than a quick course. Adalimumab is a maintenance medicine, and in a real-world study people had taken it for a median of more than three and a half years1. Some people do try stopping later with their specialist, but there is no set finish line. How long you stay on it depends on how your eye behaves and what you and your doctor decide together over time.
No. Adalimumab may control uveitis but will not cure it, which is why doctors ask you to keep taking it even when you feel well2. Think of it as holding the inflammation down rather than removing the underlying tendency toward it. That distinction is the reason stopping too soon so often lets the inflammation return, as the research below shows.
Not on your own. Feeling normal is good, but it is not proof the uveitis is gone. In a trial, about 70 of every 100 people had kept their uveitis controlled for more than two years on adalimumab but still had a high risk of recurrence3. If you want to try coming off, raise it with your specialist so it can be done as a planned, closely monitored step rather than an abrupt stop between appointments.
Adalimumab is injected under the skin using a prefilled syringe, pen, or injection device, and your doctor sets how often based on your condition and age2. Many people learn to give the injection themselves at home, or a caregiver helps. Your care team will train you on the technique, where to inject, and how to store the medicine before you do it on your own.
Because the medicine lowers your immune defenses. Before starting, your doctor tests you for tuberculosis and may check for hepatitis B, because adalimumab can reactivate a hidden infection2. If a test is positive, that infection is treated first. This is a routine safety step that protects you, not a sign that anything is wrong.
Often, yes, and that is a common reason it is prescribed. In a real-world study, starting adalimumab was linked with a drop in oral steroid use, from about 87 of every 100 patients to about 25 of every 1001. Lowering long-term steroids can spare you their side effects. Any change to your steroid dose should be guided by your doctor, not done suddenly on your own.
More Questions About Staying On, Stopping, and Safety
A flare after stopping is common, but it is usually treatable. In the trial, among people whose inflammation returned after stopping, restarting adalimumab brought it back under control3. The main risk of a flare is the inflammation itself, so report new eye symptoms quickly. The sooner a returning flare is caught, the sooner your specialist can restart or adjust treatment to protect your vision.
Many people do take it long term under supervision, and a real-world study reported sustained effectiveness and safety over a median of more than three and a half years of use1. The main ongoing risk to watch is infection, so keep your follow-up visits and report signs of infection early. Long-term use is a monitored balance between keeping your eye calm and managing that infection risk with your team.
Two things above all: infection and returning eye inflammation. Contact your doctor promptly for a fever, chills, a persistent cough, or other signs of infection2. See your eye doctor right away for new eye pain, redness, light sensitivity, or a change in vision4. Everything else, including mild injection-site reactions, can usually wait for a routine visit, but these two categories should not.
- How long do you expect me to stay on adalimumab, and what would make you consider stopping?
- If we ever try stopping, how closely will you monitor my eyes, and what is my personal risk of a flare?
- What specific infection symptoms should make me call you the same day?
- Which vaccines should I have, and are any I should avoid while on this medicine?
- Can adalimumab let me lower or stop my steroids, and on what schedule?
- Who should I contact first if my eye flares, and how do I reach them urgently?
- PMC (peer-reviewed, PMC12540958) (2025). Adalimumab in non-infectious uveitis, towards a real-world therapeutic paradigm beyond inflammation control: A multicenter cross-sectional study.
- MedlinePlus (U.S. National Library of Medicine) (2024). Adalimumab Injection.
- National Eye Institute (NEI/NIH) (2024). Treatment pause leads to high rate of relapse in children with a type of autoimmune eye inflammation (ADJUST trial).
- National Eye Institute (NEI/NIH) (2023). Uveitis.